This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: National Cerebral and Cardiovascular Center. Active years: 2022-2026.
Company Filing History:
Years Active: 2022-2026
Title: Keisuke Tachibana: Innovator in Antisense Nucleic Acid Technology
Introduction
Keisuke Tachibana is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical products, particularly in the development of therapeutic agents for diseases associated with high LDL cholesterol levels. His innovative work has led to the creation of a unique oligonucleotide conjugate that targets the human PCSK9 gene.
Latest Patents
Keisuke Tachibana holds a patent for an antisense nucleic acid targeting PCSK9. This patent describes an oligonucleotide conjugate that includes an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules. The oligonucleotide comprises a locked nucleoside analog with a bridging structure between the 4' and 2' positions. It is complementary to the human PCSK9 gene and exhibits inhibitory activity on its expression. This invention has potential applications in the pharmaceutical industry, particularly for developing therapeutic agents aimed at lowering LDL cholesterol levels.
Career Highlights
Keisuke Tachibana is affiliated with the National Cerebral and Cardiovascular Center, where he continues to advance his research and innovations. His work is instrumental in addressing critical health issues related to cardiovascular diseases.
Collaborations
Some of his notable coworkers include Mariko Harada-Shiba and Fumito Wada, who contribute to the collaborative efforts in research and development within the center.
Conclusion
Keisuke Tachibana's contributions to antisense nucleic acid technology exemplify the impact of innovative research in the pharmaceutical field. His work not only enhances our understanding of gene expression but also paves the way for new therapeutic solutions.